Endometrial cancer and venous thromboembolism in women under age 50 who take tamoxifen for prevention of breast cancer: A systematic review

Cancer Treatment Reviews

Volumn 38, Issue 4, 2012, Pages 318-328

  Iqbal, Javaid ^a   Ginsburg, Ophira M ^a,b   Wijeratne, Thiwanka D ^c   Howell, Anthony ^d   Evans, Gareth ^d   Sestak, Ivana ^e   Narod, Steven A ^a  

^a WOMEN S COLLEGE HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c QUEEN S UNIVERSITY   (Canada)

^d CHRISTIE HOSPITAL   (United Kingdom)

^e QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Breast cancer; Chemoprevention; Deep vein thrombosis; Endometrial cancer; Pulmonary embolism; Tamoxifen; Young women

Indexed keywords

TAMOXIFEN;

AGE DISTRIBUTION; BREAST CANCER; CANCER PREVENTION; CANCER RISK; COCHRANE LIBRARY; DEEP VEIN THROMBOSIS; DRUG SAFETY; ENDOMETRIUM BIOPSY; ENDOMETRIUM CANCER; FOLLOW UP; HIGH RISK POPULATION; HUMAN; LUNG EMBOLISM; PATIENT COUNSELING; PATIENT EDUCATION; POSTMENOPAUSE; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

ADULT; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN; VENOUS THROMBOEMBOLISM;

EID: 84859159506     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2011.06.009     Document Type: Review

References (62)

1. Hutchins L.F., Green S.J., Ravdin P.M., Lew D., Martino S., Abeloff M., et al. Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup Protocol INT-0102. J Clin Oncol 2005, 23(33):8313-8321.
2. Colleoni M., Gelber S., Goldhirsch A., Aebi S., Castiglione-Gertsch M., Price K.N., et al. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: international Breast Cancer Study Group Trial 13-93. J Clin Oncol 2006, 24(9):1332-1341.
3. Bramwell V.H., Pritchard K.I., Tu D., Tonkin K., Vachhrajani H., Vandenberg T.A., et al. A randomized placebo-controlled study of tamoxifen after adjuvant chemotherapy in premenopausal women with early breast cancer (National Cancer Institute of Canada - Clinical Trials Group Trial, MA.12). Ann Oncol 2010, 21(2):283-290.
4. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365(9472):1687-717.
5. Fisher B., Costantino J.P., Wickerham D.L., Redmond C.K., Kavanah M., Cronin W.M., et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998, 90(18):1371-1388.
6. Cuzick J., Forbes J., Edwards R., Baum M., Cawthorn S., Coates A., et al. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet 2002, 360(9336):817-824.
7. Powles T., Eeles R., Ashley S., Easton D., Chang J., Dowsett M., et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 1998, 352(9122):98-101.
8. Veronesi U., Maisonneuve P., Costa A., Sacchini V., Maltoni C., Robertson C., et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study. Lancet 1998, 352(9122):93-97.
9. Gail M.H., Brinton L.A., Byar D.P., Corle D.K., Green S.B., Schairer C., et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989, 81(24):1879-1886.
10. Gail M.H. The estimation and use of absolute risk for weighing the risks and benefits of selective estrogen receptor modulators for preventing breast cancer. Ann N Y Acad Sci. 2001, 949:286-291.
11. Fisher B., Costantino J.P., Wickerham D.L., Cecchini R.S., Cronin W.M., Robidoux A., et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 2005, 97(22):1652-1662.
12. Cuzick J., Forbes J.F., Sestak I., Cawthorn S., Hamed H., Holli K., et al. Long-term results of tamoxifen prophylaxis for breast cancer - 96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst 2007, 99(4):272-282.
13. Cuzick J., Powles T., Veronesi U., Forbes J., Edwards R., Ashley S., et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet 2003, 361(9354):296-300.
14. FDA. Available from: http://www.fda.gov/NewsEvents/Testimony/ucm115118.htm.
15. Waters E.A., Cronin K.A., Graubard B.I., Han P.K., Freedman A.N. Prevalence of tamoxifen use for breast cancer chemoprevention among US women. Cancer Epidemiol Biomarkers Prev 2010, 19(2):443-446.
16. Higgins JPT GSe. Cochrane handbook for systematic reviews of interventions version 5.0.2 updated September 2009. The Cochrane Collaboration; 2008. Available from: http://wwwcochrane-handbookorg.
17. Edwards P., Clarke M., DiGuiseppi C., Pratap S., Roberts I., Wentz R. Identification of randomized controlled trials in systematic reviews: accuracy and reliability of screening records. Stat Med 2002, 21(11):1635-1640.
18. CENTRAL. Available from: http://www.onlinelibrary.wiley.com/o/cochrance/cochrane_clcentral_articles_fs.html.
19. NLM. Available from: http://www.gateway.nlm.nih.gov.
20. RG O. Evaluating coding decisions. In: Cooper H, Hedges LV, editors. The handbook of research synthesis. New York (NY): Russell Sage Foundation; 1994.
21. BR K. Essentials of Medical Statistics. Blackwell Scientific Publications; 1988. ISBN 0-632-01052-5:129-30.
22. Powles T.J., Ashley S., Tidy A., Smith I.E., Dowsett M. Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J Natl Cancer Inst 2007, 99(4):283-290.
23. Altekruse SFKC, Krapcho M, Neyman N, Aminou R, Waldron W, Ruhl J, Howlader N, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Cronin K, Chen HS, Feuer EJ, Stinchcomb DG, Edwards BK, editors. SEER Cancer Statistics Review, 1975-2007, National Cancer Institute. Bethesda, MD. Based on November 2009 SEER data submission, posted to the SEER web site, 2010.
24. Cushman M., Kuller L.H., Prentice R., Rodabough R.J., Psaty B.M., Stafford R.S., et al. Estrogen plus progestin and risk of venous thrombosis. JAMA 2004, 292(13):1573-1580.
25. Anderson G.L., Limacher M., Assaf A.R., Bassford T., Beresford S.A., Black H., et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004, 291(14):1701-1712.
26. Rossouw J.E., Anderson G.L., Prentice R.L., LaCroix A.Z., Kooperberg C., Stefanick M.L., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002, 288(3):321-333.
27. Ragaz J.J.S., Coldman A., Mihalcioiu C. Is tamoxifen prevention in younger women underutilized? Analysis of competing causes of mortality. J Clin Oncol Abstract 2006, 24(18S):647.
28. Kaplan C.P., Haas J.S., Perez-Stable E.J., Gregorich S.E., Somkin C., Des Jarlais G., et al. Breast cancer risk reduction options: awareness, discussion, and use among women from four ethnic groups. Cancer Epidemiol Biomarkers Prev 2006, 15(1):162-166.
29. Yeomans-Kinney A., Vernon S.W., Frankowski R.F., Weber D.M., Bitsura J.M., Vogel V.G. Factors related to enrollment in the breast cancer prevention trial at a comprehensive cancer center during the first year of recruitment. Cancer 1995, 76(1):46-56.
30. Port E.R., Montgomery L.L., Heerdt A.S., Borgen P.I. Patient reluctance toward tamoxifen use for breast cancer primary prevention. Ann Surg Oncol 2001, 8(7):580-585.
31. Taylor R., Taguchi K. Tamoxifen for breast cancer chemoprevention: low uptake by high-risk women after evaluation of a breast lump. Ann Fam Med 2005, 3(3):242-247.
32. Heisey R., Pimlott N., Clemons M., Cummings S., Drummond N. Women's views on chemoprevention of breast cancer: qualitative study. Can Fam Physician 2006, 52:624-625.
33. Kinney A.Y., Richards C., Vernon S.W., Vogel V.G. The effect of physician recommendation on enrollment in the Breast Cancer Chemoprevention Trial. Prev Med 1998, 27(5 Pt 1):713-719.
34. Kaplan C.P., Haas J.S., Perez-Stable E.J., Des Jarlais G., Gregorich S.E. Factors affecting breast cancer risk reduction practices among California physicians. Prev Med 2005, 41(1):7-15.
35. Vogel V.G., Costantino J.P., Wickerham D.L., Cronin W.M., Cecchini R.S., Atkins J.N., et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006, 295(23):2727-2741.
36. Vogel V.G., Costantino J.P., Wickerham D.L., Cronin W.M., Cecchini R.S., Atkins J.N., et al. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: preventing breast cancer. Cancer Prev Res (Phila) 2010, 3(6):696-706.
37. LaCroix A.Z., Powles T., Osborne C.K., Wolter K., Thompson J.R., Thompson D.D., et al. Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women. J Natl Cancer Inst 2010, 102(22):1706-1715.
38. Gal D., Kopel S., Bashevkin M., Lebowicz J., Lev R., Tancer M.L. Oncogenic potential of tamoxifen on endometria of postmenopausal women with breast cancer - preliminary report. Gynecol Oncol 1991, 42(2):120-123.
39. Lahti E., Blanco G., Kauppila A., Apaja-Sarkkinen M., Taskinen P.J., Laatikainen T. Endometrial changes in postmenopausal breast cancer patients receiving tamoxifen. Obstet Gynecol 1993, 81(5 Pt 1):660-664.
40. Cohen I., Rosen D.J., Shapira J., Cordoba M., Gilboa S., Altaras M.M., et al. Endometrial changes with tamoxifen: comparison between tamoxifen-treated and nontreated asymptomatic, postmenopausal breast cancer patients. Gynecol Oncol 1994, 52(2):185-190.
41. Kedar R.P., Bourne T.H., Powles T.J., Collins W.P., Ashley S.E., Cosgrove D.O., et al. Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial. Lancet 1994, 343(8909):1318-1321.
42. Chang J., Powles T.J., Ashley S.E., Iveson T., Gregory R.K., Dowsett M. Variation in endometrial thickening in women with amenorrhea on tamoxifen. Breast Cancer Res Treat 1998, 48(1):81-85.
43. Chalas E., Costantino J.P., Wickerham D.L., Wolmark N., Lewis G.C., Bergman C., et al. Benign gynecologic conditions among participants in the Breast Cancer Prevention Trial. Am J Obstet Gynecol 2005, 192(4):1230-1237. discussion 7-9.
44. Day R., Ganz P.A., Costantino J.P., Cronin W.M., Wickerham D.L., Fisher B. Health-related quality of life and tamoxifen in breast cancer prevention: a report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Clin Oncol 1999, 17(9):2659-2669.
45. Fallowfield L., Fleissig A., Edwards R., West A., Powles T.J., Howell A., et al. Tamoxifen for the prevention of breast cancer: psychosocial impact on women participating in two randomized controlled trials. J Clin Oncol 2001, 19(7):1885-1892.
46. Cuzick J., Sestak I., Cella D., Fallowfield L., Group A.T. Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial. Lancet Oncol 2008, 9(12):1143-1148.
47. Decensi A., Maisonneuve P., Rotmensz N., Bettega D., Costa A., Sacchini V., et al. Effect of tamoxifen on venous thromboembolic events in a breast cancer prevention trial. Circulation 2005, 111(5):650-656.
48. Gail M.H., Costantino J.P., Bryant J., Croyle R., Freedman L., Helzlsouer K., et al. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst 1999, 91(21):1829-1846.
49. Hershman D., Sundararajan V., Jacobson J.S., Heitjan D.F., Neugut A.I., Grann V.R. Outcomes of tamoxifen chemoprevention for breast cancer in very high-risk women: a cost-effectiveness analysis. J Clin Oncol 2002, 20(1):9-16.
50. Cykert S., Phifer N., Hansen C. Tamoxifen for breast cancer prevention: a framework for clinical decisions. Obstet Gynecol 2004, 104(3):433-442.
51. Noe L.L., Becker R.V., Gradishar W.J., Gore M., Trotter J.P. The cost effectiveness of tamoxifen in the prevention of breast cancer. Am J Manag Care 1999, 5(6 Suppl):S389-S406.
52. Sutherland R.L., Watts C.K., Hall R.E., Ruenitz P.C. Mechanisms of growth inhibition by nonsteroidal antioestrogens in human breast cancer cells. J Steroid Biochem 1987, 27(4-6):891-897.
53. Haugan Moi L.L., Hauglid Flageng M., Gandini S., Guerrieri-Gonzaga A., Bonanni B., Lazzeroni M., et al. Effect of low-dose tamoxifen on steroid receptor coactivator 3/amplified in breast cancer 1 in normal and malignant human breast tissue. Clin Cancer Res 2010, 16(7):2176-2186.
54. Decensi A., Bonanni B., Guerrieri-Gonzaga A., Gandini S., Robertson C., Johansson H., et al. Biologic activity of tamoxifen at low doses in healthy women. J Natl Cancer Inst 1998, 90(19):1461-1467.
55. Decensi A., Gandini S., Guerrieri-Gonzaga A., Johansson H., Manetti L., Bonanni B., et al. Effect of blood tamoxifen concentrations on surrogate biomarkers in a trial of dose reduction in healthy women. J Clin Oncol 1999, 17(9):2633-2638.
56. Decensi A., Robertson C., Viale G., Pigatto F., Johansson H., Kisanga E.R., et al. A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers. J Natl Cancer Inst 2003, 95(11):779-790.
57. Bernardes J.R., Nonogaki S., Seixas M.T., Rodrigues de Lima G., Baracat E.C., Gebrim L.H. Effect of a half dose of tamoxifen on proliferative activity in normal breast tissue. Int J Gynaecol Obstet 1999, 67(1):33-38.
58. de Lima G.R., Facina G., Shida J.Y., Chein M.B., Tanaka P., Dardes R.C., et al. Effects of low dose tamoxifen on normal breast tissue from premenopausal women. Eur J Cancer 2003, 39(7):891-898.
59. Nephew K.P., Osborne E., Lubet R.A., Grubbs C.J., Khan S.A. Effects of oral administration of tamoxifen, toremifene, dehydroepiandrosterone, and vorozole on uterine histomorphology in the rat. Proc Soc Exp Biol Med 2000, 223(3):288-294.
60. Li D., Dragan Y., Jordan V.C., Wang M., Pitot H.C. Effects of chronic administration of tamoxifen and toremifene on DNA adducts in rat liver, kidney, and uterus. Cancer Res 1997, 57(8):1438-1441.
61. Andersen J., Kamby C., Ejlertsen B., Cold S., Ewertz M., Jacobsen E.H., et al. Tamoxifen for one year versus two years versus 6 months of Tamoxifen and 6 months of megestrol acetate: a randomized comparison in postmenopausal patients with high-risk breast cancer (DBCG 89C). Acta Oncol 2008, 47(4):718-724.
62. Cook L.S., Weiss N.S., Schwartz S.M., White E., McKnight B., Moore D.E., et al. Population-based study of tamoxifen therapy and subsequent ovarian, endometrial, and breast cancers. J Natl Cancer Inst 1995, 87(18):1359-1364.